TRIDENT-1

NCT03093116 📎

Regimen

Experimental
repotrectinib
Control
none

Population

ROS1+ NSCLC TKI-naive and pre-treated

Key finding

TKI-naive ORR 79% (68-88), mPFS 35.7 mo; TKI-pretreated ORR 38%; next-gen ROS1 covering G2032R

Source: PMID 38197815

Timeline

  • Enrollment start: 2017-03-07 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.113)
  • CSCO NSCLC 2025 ⚠️ OCR source